Unicentric Form of Castleman Disease – Surgery Therapy Benefit

checkorphan
Learn more about:
Castleman’s disease
Related Clinical Trial
Unicentric Form of Castleman Disease – Surgery Therapy Benefit International Registry for Patients With Castleman Disease A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman’s Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease Castleman Disease Collaborative Network Biobank Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Brief Title

Unicentric Form of Castleman Disease - Surgery Therapy Benefit

Official Title

Castleman Disease - Diagnosis and Surgery

Brief Summary

      Observation study on patients with unicentric form of Castleman disease, evaluation of
      surgical treatment benefit. Observation of surgical treatment strategy.

Study Type

Observational

Primary Outcome

5 year survival

Condition

Castleman Disease

Intervention

surgery type/exstirpation/debulking

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Procedure

Estimated Enrollment

20

Start Date

January 1, 2011

Completion Date

April 30, 2022

Primary Completion Date

December 31, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  patient with unicentric form of Castleman disease

          -  underwent surgery resection

        Exclusion Criteria:

          -  multilocalised Castleman disease

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

, ,

Administrative Informations

NCT ID

NCT05440305

Organization ID

750923

Responsible Party

Principal Investigator

Study Sponsor

Charles University, Czech Republic

Study Sponsor

, ,

Verification Date

June 2022